Ronald W. Mink, Ph.D., Member of the Board
Dr. Mink has served as President and Chief Science Officer of Sedia Biosciences since 2009 and is also a co-founder. Dr. Mink has been on the board since its founding. Previously, Dr. Mink served as Chief Science Officer (CSO) of Calypte Biosciences from June 2005 until December 2008 and as Director of R&D at Calypte from 2003 until 2005. He also served as a full time consultant for Calypte from 2001 to 2003. At Calypte, he introduced rapid point of care diagnostic testing technology to the company, established the oral fluid diagnostic product line, oversaw development of the BED HIV-1 Incidence EIA and expanded the company’s Aware? line of HIV products, and launched the creation of its new Life Sciences Division. Prior to Calypte, he was Director of R&D at OraSure Technologies, Inc. (NASDAQ: OSUR). Dr. Mink holds several patents for oral fluid diagnostic tests, including the OraQuick® HIV rapid test, the first U.S. FDA approved rapid oral fluid HIV test. and other tests for oral disease pathogens. He has prior experience successfully developing and commercializing rapid assays in such companies as Eli Lilly and Co.’s diagnostic group and Carter Wallace, culminating in the commercialization of several products including First Response® One Step Pregnancy Test, First Response® 3 Minute Ovulation Test, CARDS QS® hCG, CARDS OS® Strep B and other point-of-care and OTC tests. Dr. Mink received his Ph.D. in Microbiology from the University of Illinois and B.S. and M.S. from Ohio State University.